Clinical trials registration

N. Tiffin, J. Nickerson
{"title":"Clinical trials registration","authors":"N. Tiffin, J. Nickerson","doi":"10.1001/archpsyc.63.2.128","DOIUrl":null,"url":null,"abstract":"Over the past eight years, the registration of clinical trials has been strongly advocated by journals and editors, and is now considered to be mandatory for publication by most medical journals. In the United States, it became legally mandated by the Food and Drug Administration in 2007 (1), although Canada has no law requiring registration. Registration of a clinical trial ensures that the public has access to information regarding trials involving human subjects and health outcomes. Published clinical trials strongly affect decision making in health care, including decisions made at the bedside, in the boardroom and in the legislature. Therefore, the public needs to have access to the same evidence as the decision makers. Moreover, registering clinical trials and their protocols before data collection begins helps correct the distortion created by selective reporting in the literature (ie, ‘positive publication bias’), in which only trials with positive outcomes are published. Many also believe that the research community, by using human subjects, has a moral obligation to the public to publish their findings and a registry can reveal a disconnect in communication. In addition, registries can help standardize and improve clinical trial protocols, reduce overlapping or redundant publication and scientific misconduct, and improve accuracy in reporting. Several registries exist today, with the largest at administered by the US National Institutes of Health. Individual countries often have their own registry, many of which use the WHO’s International Clinical Trial Registry Platform guidelines. The International Committee of Medical Journal Editors has established six guidelines for the establishment of registries (2); although not all registries adhere to these guidelines, they provide insight to registry characteristics and expectations: Accessible to the public at no charge. Open to all prospective registrants. Managed by a not-for-profit organization. A mechanism to ensure the validity of the registration data must be available. Electronically searchable. Trial registration with missing fields or fields that contain uninformative terminology is inadequate. The International Committee of Medical Journal Editors defines a clinical trial as “any research project that prospectively assigns human subjects to intervention or concurrent comparison or control groups to study the cause-and-effect relationship between a medical intervention and a health outcome” (2). Health outcomes are further defined as “any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events” (3). In the current issue of the Canadian Journal of Respiratory Therapy, the study by Matthews and Fortier (4) (pages 11–14) – ‘The Rematee Bumper Belt positional therapy device for snoring and obstructive sleep apnea: Positional effectiveness in healthy subjects’ – has not been registered as a clinical trial despite the use of human subjects. Why? First, although the editorial board of the Journal strongly support registration of clinical trials, we do not believe that the study’s dependent variable – sleeping position – reached the definition of a health outcome. In addition, we believed that because the main reason for registration is to ensure the publication of important findings and the authors had submitted the manuscript for publication, this became a moot criterion. Although the Journal strongly believes in the value of clinical trials registration, we believed that, on balance, the rejection of an article reporting on a completed study solely on the basis of the absence of clinical trial registration was not in the best interests of patients nor health care providers. In making this decision, we consulted with experts in medical publishing and in clinical trials registration, and believe this to have been the most appropriate decision. As the Journal progresses in reputation and quality, we anticipate more submissions of clinical trial manuscripts and have been prompted by this particular article to codify a policy for clinical trial publication criteria that will be communicated in 2014. Going forward, we strongly encourage all authors and investigators to prospectively register their clinical trials in advance of conducting data collection. It is our intention to include these details in the publication of clinical trials manuscripts to enhance the transparency and quality of respiratory therapy research.","PeriodicalId":9533,"journal":{"name":"Canadian Journal of Respiratory Therapy: CJRT = Revue Canadienne de la Thérapie Respiratoire : RCTR","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"10","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Canadian Journal of Respiratory Therapy: CJRT = Revue Canadienne de la Thérapie Respiratoire : RCTR","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1001/archpsyc.63.2.128","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 10

Abstract

Over the past eight years, the registration of clinical trials has been strongly advocated by journals and editors, and is now considered to be mandatory for publication by most medical journals. In the United States, it became legally mandated by the Food and Drug Administration in 2007 (1), although Canada has no law requiring registration. Registration of a clinical trial ensures that the public has access to information regarding trials involving human subjects and health outcomes. Published clinical trials strongly affect decision making in health care, including decisions made at the bedside, in the boardroom and in the legislature. Therefore, the public needs to have access to the same evidence as the decision makers. Moreover, registering clinical trials and their protocols before data collection begins helps correct the distortion created by selective reporting in the literature (ie, ‘positive publication bias’), in which only trials with positive outcomes are published. Many also believe that the research community, by using human subjects, has a moral obligation to the public to publish their findings and a registry can reveal a disconnect in communication. In addition, registries can help standardize and improve clinical trial protocols, reduce overlapping or redundant publication and scientific misconduct, and improve accuracy in reporting. Several registries exist today, with the largest at administered by the US National Institutes of Health. Individual countries often have their own registry, many of which use the WHO’s International Clinical Trial Registry Platform guidelines. The International Committee of Medical Journal Editors has established six guidelines for the establishment of registries (2); although not all registries adhere to these guidelines, they provide insight to registry characteristics and expectations: Accessible to the public at no charge. Open to all prospective registrants. Managed by a not-for-profit organization. A mechanism to ensure the validity of the registration data must be available. Electronically searchable. Trial registration with missing fields or fields that contain uninformative terminology is inadequate. The International Committee of Medical Journal Editors defines a clinical trial as “any research project that prospectively assigns human subjects to intervention or concurrent comparison or control groups to study the cause-and-effect relationship between a medical intervention and a health outcome” (2). Health outcomes are further defined as “any biomedical or health-related measures obtained in patients or participants, including pharmacokinetic measures and adverse events” (3). In the current issue of the Canadian Journal of Respiratory Therapy, the study by Matthews and Fortier (4) (pages 11–14) – ‘The Rematee Bumper Belt positional therapy device for snoring and obstructive sleep apnea: Positional effectiveness in healthy subjects’ – has not been registered as a clinical trial despite the use of human subjects. Why? First, although the editorial board of the Journal strongly support registration of clinical trials, we do not believe that the study’s dependent variable – sleeping position – reached the definition of a health outcome. In addition, we believed that because the main reason for registration is to ensure the publication of important findings and the authors had submitted the manuscript for publication, this became a moot criterion. Although the Journal strongly believes in the value of clinical trials registration, we believed that, on balance, the rejection of an article reporting on a completed study solely on the basis of the absence of clinical trial registration was not in the best interests of patients nor health care providers. In making this decision, we consulted with experts in medical publishing and in clinical trials registration, and believe this to have been the most appropriate decision. As the Journal progresses in reputation and quality, we anticipate more submissions of clinical trial manuscripts and have been prompted by this particular article to codify a policy for clinical trial publication criteria that will be communicated in 2014. Going forward, we strongly encourage all authors and investigators to prospectively register their clinical trials in advance of conducting data collection. It is our intention to include these details in the publication of clinical trials manuscripts to enhance the transparency and quality of respiratory therapy research.
临床试验注册
在过去的八年中,临床试验的注册一直受到期刊和编辑的强烈倡导,现在被认为是大多数医学期刊发表的强制性要求。在美国,2007年食品和药物管理局(Food and Drug Administration)在法律上强制要求(1),尽管加拿大没有法律要求注册。临床试验的注册确保公众能够获得有关涉及人体受试者和健康结果的试验的信息。已发表的临床试验强烈地影响着医疗保健方面的决策,包括床边、董事会和立法机构的决策。因此,公众需要获得与决策者相同的证据。此外,在数据收集开始之前注册临床试验及其方案有助于纠正文献选择性报告造成的扭曲(即“积极发表偏倚”),其中只发表具有积极结果的试验。许多人还认为,研究界通过使用人类受试者,对公众负有发表他们的发现的道德义务,而登记可以揭示沟通上的脱节。此外,注册可以帮助规范和改进临床试验方案,减少重叠或冗余的出版和科学不端行为,并提高报告的准确性。目前存在几个登记处,其中最大的由美国国立卫生研究院管理。个别国家通常有自己的注册中心,其中许多使用世卫组织的国际临床试验注册平台指南。国际医学期刊编辑委员会为建立登记制度制定了六项准则(2);尽管并非所有注册中心都遵循这些指导方针,但它们提供了对注册中心特征和期望的洞察:对公众免费开放。对所有潜在注册人开放。由非营利组织管理。必须有确保注册数据有效性的机制。电子搜索。缺少字段或包含无信息术语的字段的试验注册是不充分的。国际医学杂志编辑委员会将临床试验定义为“任何研究项目,将人类受试者分配到干预组或同时比较组或对照组,以研究医疗干预与健康结果之间的因果关系”(2)。健康结果进一步定义为“在患者或参与者身上获得的任何生物医学或健康相关措施,包括药代动力学测量和不良事件”(3)。在最新一期的《加拿大呼吸治疗杂志》上,Matthews和Fortier的研究(11-14页)——“Rematee保险杠带体位治疗打鼾和阻塞性睡眠呼吸暂停的装置:健康受试者的体位有效性”——尽管使用了人类受试者,但尚未注册为临床试验。为什么?首先,尽管《华尔街日报》的编辑委员会强烈支持临床试验的注册,但我们不相信这项研究的因变量——睡眠姿势——达到了健康结果的定义。此外,我们认为,由于注册的主要原因是为了确保重要发现的发表,并且作者已经提交了稿件供发表,因此这成为一个没有实际意义的标准。尽管《华尔街日报》坚信临床试验注册的价值,但我们认为,总的来说,仅仅因为缺乏临床试验注册而拒绝一篇报道已完成研究的文章并不符合患者和卫生保健提供者的最佳利益。在做出这一决定时,我们咨询了医学出版和临床试验注册方面的专家,并认为这是最合适的决定。随着期刊在声誉和质量方面的进步,我们预计会有更多的临床试验稿件提交,并且受到这篇特殊文章的启发,我们将编纂一项临床试验发表标准政策,该政策将于2014年发布。展望未来,我们强烈鼓励所有作者和研究者在进行数据收集之前前瞻性地注册他们的临床试验。我们打算将这些细节包括在临床试验手稿的出版中,以提高呼吸治疗研究的透明度和质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信